Novo Nordisk A/S — Form 6-K summary
Filing date: October 5, 2026. The filing reports share repurchases under the company’s 2026 buyback programme; it does not report quarterly or annual operating results.
Programme and transactions
- The overall programme authorizes repurchases of up to DKK 15 billion over 12 months beginning February 4, 2026.
- A programme initiated May 6, 2026, authorizes up to DKK 11.2 billion in B-share repurchases through February 1, 2027.
- From September 28 through October 2, Novo Nordisk repurchased 1,225,000 B shares for approximately DKK 307.4 million.
- Cumulative purchases under the May programme were 21,845,000 shares for DKK 6.447 billion. Since February 4, cumulative purchases across the overall programme were 36,604,179 shares at an average DKK 279.95 per share, for DKK 10.247 billion, as of October 2.
- Following the reported transactions, the company held 50,644,876 B shares as treasury shares, equal to 1.1% of share capital. Total A and B shares, including treasury shares, were 4.465 billion.
Financial metrics and period comparison
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures, and no comparable-period operating data. It is a buyback update rather than an earnings report.
Outlook, risks, and unusual items
Novo Nordisk expects to repurchase up to DKK 15 billion of shares during the 12-month period beginning February 4, 2026. The filing gives no further business guidance, risk update, or contingency information. Repurchases are stated to be conducted under applicable EU market-abuse safe-harbour rules.
Investor facts to verify
- Whether subsequent repurchases remain within the DKK 15 billion overall limit and the DKK 11.2 billion May-programme limit.
- Updated cumulative repurchases, treasury-share holdings, and remaining authorization in later company announcements.
- The effect of repurchases on share count, capital allocation, and liquidity; this filing does not quantify those effects.